Clinical Trial: High-dose ICE With Amifostine

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection

Brief Summary: The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.

Detailed Summary:
Sponsor: Dana-Farber Cancer Institute

Current Primary Outcome: Percentage of Participants with Grade 2 or higher renal toxicities [ Time Frame: 2 Months ]

Original Primary Outcome:

Current Secondary Outcome: Full Pharmacokinetic profiles for ifosfamide and its metabolites MTD of ICE with amifostine [ Time Frame: 2 Months ]

Original Secondary Outcome:

Information By: Dana-Farber Cancer Institute

Dates:
Date Received: November 1, 1999
Date Started: July 1998
Date Completion:
Last Updated: January 19, 2017
Last Verified: January 2017